Global Enzymatic Wound Debridement Market, By Type (Chronic Wound, Acute Wound), Product (Collagenase Product, Papain Product, Others), Dosage (Ointment, Gel, Spray Emulsion, Dressing), End User (Hospitals, Homecare, Others) – Industry Trends and Forecast to 2030.
Enzymatic Wound Debridement Market Analysis and Size
Over 100 million Americans have diabetes or prediabetes, according to the CDC's National Diabetes Statistic Report 2017, which was released in 2017. Furthermore, according to the International Diabetes Federation, there will be 552.0 million cases of diabetes worldwide by 2030, up from 366.0 million in 2011. Rising diabetes incidence is anticipated to have a favourable effect on growth since long-term diabetes might result in diabetic foot. Products made from papain and collagenase are mostly used to treat pressure ulcers, venous leg ulcers, and diabetic foot ulcers.
Data Bridge Market Research analyses that the enzymatic wound debridement market which is USD 884.45 million in 2022, is expected to reach USD 1441.91 million by 2030, at a CAGR of 6.3% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Enzymatic Wound Debridement Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Chronic Wound, Acute Wound), Product (Collagenase Product, Papain Product, Others), Dosage (Ointment,Gel, Spray Emulsion, Dressing), End User (Hospitals, Homecare, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Smith+Nephew (U.K.), ConvaTec Inc. (U.K.), PAUL HARTMANN AG (Germany), Integra LifeSciences (U.S.), Medline Industries, Inc. (U.S.), B. Braun SE (Germany), RLS Global (Sweden), Solsys Medical (U.S.), Mölnlycke Health Care AB (Sweden), DeRoyal Industries (U.S.), MediWound (Germany), Healthpoint, Ltd (U.K.), Zimmer Biomet (U.S.), Suzhou and Science & Technology Development Corp (China), Lohmann & Rauscher GmbH & Co. KG (Germany), PulseCare Medical (U.S.), BioMonde (U.K.), Bioventus LLC (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Debridement is a surgical procedure that removes infected and dead tissues in order to heal a wound. Enzymatic debridement is one of the selective wound debridement methods. Enzymes used in wound debridement break down collagen and other proteins required for the growth of infectious tissues. They also help to remove dead tissues from the wound.
Enzymatic Wound Debridement Market Dynamics
Drivers
- Rise in cancer cases
According to the WHO, cancer is the biggest cause of mortality worldwide, accounting for about one in every six fatalities. Additionally, middle- and low-income nations account for approximately 70% of deaths from cancer. As the second most common cause of death, cancer is regarded as a significant healthcare burden worldwide. About 1,658,716 new cases of cancer were reported in the United States in 2016, according to the CDC. With more than half of the adult population suffering from chronic diseases, which account for more than 75% of the nation's overall healthcare expenditures, chronic diseases are another significant healthcare concern in the United States. These are the certain factors which propel the growth of market.
Opportunities
- Rise in the number of mishaps
It is also expected that a rise in the number of mishaps, such as burns, trauma, and road accidents, will spur expansion. For instance, according to WHO (2018), around 1,000,000 persons in India suffer severe or moderate burns every year. Additionally, the NCBI reports that in 2017, the incidence of burn wounds increased in nations like Bulgaria, Finland, the Netherlands, China, Australia, and the United Kingdom. Additionally, according to the American Association for the Surgery of Trauma, 3,242 people die in traffic accidents every day, or around 1.2 million individuals worldwide lost their lives in 2017. In light of this, it is anticipated that an increase in accidents will increase demand for enzymatic wound debridement solutions, leading to significant growth during the forecast period.
Restraints/Challenges
- High costs associated with chronic wound treatment
The high costs associated with chronic wound treatment are expected to stymie the global enzymatic wound debridement market in the coming years. According to a study published in the Journal of Medical Economics, the direct cost of collagenase debridement is higher than that of hydrogel debridement.
This enzymatic wound debridement market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the enzymatic wound debridement market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Enzymatic Wound Debridement Market Scope
The enzymatic wound debridement market is segmented on the basis of type, product, dosage and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Chronic Wounds
- Diabetic Foot Ulcers
- Pressure Ulcers
- Venous Leg Ulcers
- Acute Wounds
- Burn
- Other Acute Wounds
Product
- Collagenase Product
- Papain Product
- Others
Dosage
- Ointment
- Topical
- Gel
- Spray Emulsion
- Dressing
End-use
- Hospitals
- Homecare
- Others
Enzymatic Wound Debridement Market Regional Analysis/Insights
The enzymatic wound debridement market is analyzed and market size insights and trends are provided by country, type, product, dosage and end user as referenced above.
The countries covered in the enzymatic wound debridement market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the enzymatic wound debridement market because sports injuries and traffic accidents are increasing. Enzymatic wound debridement market expansion in the area will also be aided by the presence of numerous prominent players throughout the course of the forecast year.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because of the development of advanced nations. In the upcoming years, it is also projected that the region's enzymatic wound debridement market will expand due to the expansion of the medical tourism industry.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The enzymatic wound debridement market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for enzymatic wound debridement market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the enzymatic wound debridement market. The data is available for historic period 2011-2021
Competitive Landscape and Enzymatic Wound Debridement Market Share Analysis
The enzymatic wound debridement market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to enzymatic wound debridement market.
Some of the major players operating in the enzymatic wound debridement market are:
- Smith+Nephew (U.K.)
- ConvaTec Inc. (U.K.)
- PAUL HARTMANN AG (Germany)
- Integra LifeSciences (U.S.)
- Medline Industries, Inc. (U.S.)
- B. Braun SE (Germany)
- RLS Global (Sweden)
- Solsys Medical (U.S.)
- Mölnlycke Health Care AB (Sweden)
- DeRoyal Industries (U.S.)
- MediWound (Germany)
- Healthpoint, Ltd (U.K.)
- Zimmer Biomet (U.S.)
- Suzhou and Science & Technology Development Corp (China)
- Lohmann & Rauscher GmbH & Co. KG (Germany)
- PulseCare Medical (U.S.)
- BioMonde (U.K.)
- Bioventus LLC (U.S.)
SKU-